Compare Stocks: INVA, LQDA, AMRX, and DFTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.77 -0.2%	$18.07	$9.56 ▼ $21.17	$6.31B	1.24	2.42 million shs	2.52 million shs
DFTX Definium Therapeutics	$36.17 -1.5%	$41.59	$9.62 ▼ $49.70	$4.86B	2.23	2.19 million shs	2.68 million shs
INVA Innoviva	$20.74 +0.4%	$21.05	$16.52 ▼ $25.15	$1.50B	0.33	979,238 shs	623,372 shs
LQDA Liquidia	$68.43 -3.6%	$75.40	$21.15 ▼ $93.61	$6.13B	0.53	1.16 million shs	967,315 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+9.77%	+14.74%	+103.60%
DFTX Definium Therapeutics	0.00%	-6.80%	-17.46%	-19.53%	+268.33%
INVA Innoviva	0.00%	-1.89%	-1.05%	-12.01%	+9.50%
LQDA Liquidia	0.00%	+2.32%	-2.16%	-12.46%	+211.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.77 -0.2%	$18.07	$9.56 ▼ $21.17	$6.31B	1.24	2.42 million shs	2.52 million shs
DFTX Definium Therapeutics	$36.17 -1.5%	$41.59	$9.62 ▼ $49.70	$4.86B	2.23	2.19 million shs	2.68 million shs
INVA Innoviva	$20.74 +0.4%	$21.05	$16.52 ▼ $25.15	$1.50B	0.33	979,238 shs	623,372 shs
LQDA Liquidia	$68.43 -3.6%	$75.40	$21.15 ▼ $93.61	$6.13B	0.53	1.16 million shs	967,315 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+9.77%	+14.74%	+103.60%
DFTX Definium Therapeutics	0.00%	-6.80%	-17.46%	-19.53%	+268.33%
INVA Innoviva	0.00%	-1.89%	-1.05%	-12.01%	+9.50%
LQDA Liquidia	0.00%	+2.32%	-2.16%	-12.46%	+211.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.90	Moderate Buy	$21.00	6.22% Upside
DFTX Definium Therapeutics	3.00	Buy	$64.88	79.36% Upside
INVA Innoviva	2.43	Hold	$34.80	67.79% Upside
LQDA Liquidia	2.45	Hold	$98.08	43.33% Upside

Current Analyst Ratings Breakdown

Latest INVA, LQDA, AMRX, and DFTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	INVA Innoviva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/23/2026	INVA Innoviva	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
9/22/2026	LQDA Liquidia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C)
9/22/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/15/2026	DFTX Definium Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$64.00 ➝ $78.00
9/15/2026	DFTX Definium Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$70.00
9/15/2026	DFTX Definium Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$75.00 ➝ $79.00
9/14/2026	DFTX Definium Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$75.00
9/14/2026	DFTX Definium Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$70.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.09	$1.56 per share	12.66	($0.23) per share	-85.96
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
INVA Innoviva	$440.00M	3.41	$5.03 per share	4.12	$15.71 per share	1.32
LQDA Liquidia	$450.91M	13.58	N/A	N/A	$0.51 per share	134.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	40.35	18.31	2.34	5.05%	-584.46%	7.78%	N/A
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
INVA Innoviva	$271.17M	$4.10	5.06	9.74	2.99	81.19%	28.03%	20.19%	11/4/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	49.95	15.62	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)

Latest INVA, LQDA, AMRX, and DFTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
DFTX Definium Therapeutics	0.04	6.95	6.95
INVA Innoviva	0.21	16.01	15.18
LQDA Liquidia	0.63	2.31	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
DFTX Definium Therapeutics	27.91%
INVA Innoviva	99.12%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
DFTX Definium Therapeutics	2.40%
INVA Innoviva	2.01%
LQDA Liquidia	25.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
INVA Innoviva	159	72.25 million	70.79 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable

INVA, LQDA, AMRX, and DFTX Headlines

Recent News About These Companies

Liquidia (NASDAQ:LQDA) Downgraded by Zacks Research to Strong Sell

September 24 at 6:59 AM | marketbeat.com

Can LQDA's Yutrepia Outpace Intensifying PAH Competition?

September 23, 2026 | zacks.com

Liquidia (NASDAQ:LQDA) Upgraded at Wall Street Zen

September 20, 2026 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Rating Increased to Buy at Wall Street Zen

September 20, 2026 | marketbeat.com

Raman Singh Sells 9,024 Shares of Liquidia (NASDAQ:LQDA) Stock

September 17, 2026 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Trading Up 6% - Still a Buy?

September 16, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 8,468 Shares

September 16, 2026 | insidertrades.com

Raman Singh Sells 8,468 Shares of Liquidia (NASDAQ:LQDA) Stock

September 15, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 9,024 Shares

September 15, 2026 | marketbeat.com

Squarepoint Ops LLC Trims Stock Position in Liquidia Corporation $LQDA

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Acquires 1,657 Shares of Liquidia Corporation $LQDA

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Sells 17,412 Shares of Liquidia Corporation $LQDA

September 14, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.24 Million in Liquidia Corporation $LQDA

September 13, 2026 | marketbeat.com

Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Wall Street Zen

September 12, 2026 | marketbeat.com

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

September 11, 2026 | zacks.com

Liquidia Corporation $LQDA Holdings Decreased by Opaleye Management Inc.

September 11, 2026 | marketbeat.com

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

September 10, 2026 | zacks.com

Wellington Management Group LLP Sells 22,925 Shares of Liquidia Corporation $LQDA

September 8, 2026 | marketbeat.com

Liquidia Corporation Receives FDA Fast Track Designation For YUTREPIA For Raynaud's Phenomenon Associated With Systemic Sclerosis

September 4, 2026 | marketscreener.comM

Liquidia Gains FDA Fast Track For YUTREPIA In Raynaud's Linked To Systemic Sclerosis

September 3, 2026 | rttnews.com

Liquidia Says US FDA Grants Fast Track Designation to Yutrepia in Systemic Sclerosis

September 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA, LQDA, AMRX, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$19.77 -0.04 (-0.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$19.87 +0.10 (+0.50%)

As of 09/25/2026 07:59 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Definium Therapeutics NASDAQ:DFTX

$36.17 -0.56 (-1.52%)

As of 09/25/2026 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Innoviva NASDAQ:INVA

$20.74 +0.08 (+0.39%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$20.74 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Liquidia NASDAQ:LQDA

$68.43 -2.52 (-3.55%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$69.78 +1.35 (+1.98%)

As of 09/25/2026 07:30 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INVA, LQDA, AMRX, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INVA, LQDA, AMRX, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INVA, LQDA, AMRX, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA, LQDA, AMRX, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Innoviva NASDAQ:INVA

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INVA, LQDA, AMRX, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INVA, LQDA, AMRX, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INVA, LQDA, AMRX, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA, LQDA, AMRX, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Innoviva NASDAQ:INVA

Liquidia NASDAQ:LQDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools